Application of SOX2 targeted drug to inhibiting proliferation of lung cancer stem cells

A technology of lung cancer stem cells and drugs, which can be used in drug combinations, anti-tumor drugs, pharmaceutical formulations, etc., and can solve problems such as unknown specific mechanisms.

Inactive Publication Date: 2020-10-02
滨州医学院附属医院
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And it has a certain anti-hepatitis B virus effect, which can be use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of SOX2 targeted drug to inhibiting proliferation of lung cancer stem cells
  • Application of SOX2 targeted drug to inhibiting proliferation of lung cancer stem cells
  • Application of SOX2 targeted drug to inhibiting proliferation of lung cancer stem cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0042] The above-mentioned content of the present invention will be further described in detail below through the form of specific embodiments. However, it should not be construed that the scope of the above-mentioned subject matter of the present invention is limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention.

[0043] The expression level of SOX2 in paracancerous and lung cancer tissues and its correlation with prognosis

[0044] The present invention first uses the GENT database to mine the expression of SOX2 in paracancerous tissues and lung cancer tissues, and confirms that the expression level of SOX2 in lung cancer tissues is significantly higher than that of the paired control (Pfigure 1 A). The correlation between the expression level of SOX2 and the overall survival and progression-free period of patients was detected by the cBioPortal database. In 522 patient...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of an SOX2 targeted drug to inhibiting proliferation of lung cancer stem cells. The SOX2 targeted drug is a scutellaria barbata D.Don extract; and the SOX2 targeted drug interferes with proliferation of lung cancer stem cells and multidrug resistance thereof through targeted inhibition of SOX2. The drug has toxic and side effects, and is tolerable and easy totake orally and absorb. Cell proliferation, cell apoptosis and cell cycle arrest assays prove that a polypeptide provided by the invention can effectively inhibit proliferation of tumor stem cells andthe drug has no obvious tissue damage or toxicity to mice at high doses.

Description

technical field [0001] The invention relates to the application of a SOX2-targeted drug to inhibit the proliferation of lung cancer stem cells, in particular to the application of barbatae barbata extracts to inhibit the growth of lung cancer cells and interfere with the proliferation of stem cells in vivo and in vitro by targeting the stem cell transcription factor SOX2. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality in my country. Conventional clinical treatment methods include surgical resection, targeted therapy, immunotherapy, and radiotherapy and chemotherapy. Although individualized targeted therapy such as EGFR and ALK inhibitors has achieved good therapeutic effects, patients with mutant EGFR and ALK only account for about 15% of NSCLC patients, and most patients will still develop drug resistance after 1 year of medication. Although the immunotherapy carried out in recent years has made great progress, there...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/539A61P35/00
CPCA61K36/539A61P35/00
Inventor 杜静
Owner 滨州医学院附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products